The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on Merkel cell carcinoma.

The purpose of this study is to test the safety and effectiveness of the experimental combination of tazemetostat with chimeric antigen receptor t-cell (CAR T) cell therapy, and see what effects it has on lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This clinical trial is for men and women with newly diagnosed Acute Myeloid Lymphoma (AML) who are not eligible for intensive chemotherapy.
   
The purpose of this study is to evaluate the safety and effectiveness of the addition of an experimental drug, magrolimab, in combination with venetoclax and azacitidine compared to venetoclax and azacitidine alone.
   
Experimental means that magrolimab has not yet been approved by the U.S. Food and Drug Administration (FDA).
   

This clinical trial is for adult participants who have myelofibrosis for which standard therapy has proven ineffective, or for those who cannot tolerate the standard therapy or are not able to receive the standard therapy.
   

The purpose of this study is to provide men and women with relapsed/refractory multiple myeloma (RRMM) expanded access to the antibody-drug conjugate belantamab mafodotin.

This study is open to those who are either enrolled in the BLENREP REMS (Risk Evaluation and Mitigation Strategy) program, or who have RRMM refractory to immunomodulators (IMID), proteasome inhibitors (PI), and an anti-CD38 antibody, and no suitable alternative treatment options.

The purpose of this study is to learn about changes in brain function, thoughts, feelings, and behavior that occur during treatment for depression and suicidal ideation.

Suicidality in mid- and late life is characterized with abnormalities in the Positive Valence System (PVS). The aim of the study is to examine if exposure to meaningful social rewards during psychotherapy engages PVS circuitry and improves mid- and late-life suicidality among depressed older adults.

This is a research study to evaluate the safety and tolerability of an experimental drug called TVB-2640 in combination with Enzalutamide for men with metastatic castration resistant prostate cancer (mCRPC) whose disease has progressed while taking androgen-deprivation therapy (ADT). ADT is the primary treatment method for mCRPC. This study will find the highest dose of TVB-2640 that can be given with Enzalutamide without causing severe side effects.

The overall goal of this study is to compare the effects, good and/or bad of the study drugs brentuximab vedotin and nivolumab (Bv-NIVO) against the standard therapy of chemotherapy with or without radiation for people with Hodgkin Lymphoma (HL) to find out which is better.

Treatment with brentuximab vedotin and nivolumab (Bv-NIVO) is considered investigational, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

This clinical trial is for adults who have advanced and metastatic castrate resistant prostate cancer (mCRPC).
   
The purpose of this study is to test new compounds (64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA) as possible treatment for metastatic castrate resistant prostate cancer (mCRPC), an advanced form of prostate cancer.
   

The purpose of this study is to study the safety and effects of two new immunotherapies aimed at achieving and maintaining tumor shrinkage in patients with non-microsatellite stable colorectal cancer without liver metastases.

Botensilimab (also known as AGEN1181) and balstilimab (also known as AGEN2034) are both experimental drugs, which means that neither have been approved by the U.S. Food and Drug Administration (FDA).